Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01276509 · ClinicalTrials.gov registry record · Phase 2
Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
A Phase 2 study, sponsored by Shire.
- Completed
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
NCT01276509 is a Phase 2 study that has completed, run by Shire. The registered enrollment target is 265 participants.
The verdict
NCT01276509, a Phase 2 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
Study Summary
Adults with Crohn's disease that is clinically active despite conventional treatment will be eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental drug) or placebo (inactive drug). Disease activity will be measured every two weeks.
Interventions
- DRUG PF-00547659 SC injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2011-04-06 |
| Est. Completion | 2015-10-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01276509
The ClinicalTrials.gov registry entry for NCT01276509 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-00547659 SC injection is the first listed.
NCT01276509 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01276509 about?
NCT01276509 is a clinical study titled "Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease". Adults with Crohn's disease that is clinically active despite conventional treatment will be eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental drug) or placebo (inactive drug). Disease activity will be measured every two weeks.
What is the current status of trial NCT01276509?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2011-04-06. Estimated completion is 2015-10-09.
What interventions are being tested in trial NCT01276509?
The interventions under investigation include: PF-00547659 SC injection (DRUG).
Who is sponsoring clinical trial NCT01276509?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.